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Introduction
Parkinson’s disease (PD) is one of the most common neurode-
generative disorders, affecting about 1% of the general popula-
tion older than 60-years.
1,2 In spite of marked progress in the sci-
entific understanding of this condition, its diagnosis continues 
to be based upon key clinical features.
3,4 A definitive diagnosis 
can only be made by pathologic confirmation of dopaminergic 
neuronal loss and the presence of Lewy bodies or Lewy neu-
rites in autopsied brain tissue, which has led to continued debat-
ed about the accuracy of clinical diagnoses.
3,5-7 
The Lewy body, which was first described by Friedrich Hein-
rich Lewy, is located in the neuronal cytoplasm and is a patho-
logical hallmark of and dementia with Lewy bodies.
8 This fila-
mentous spherical inclusion is composed of ubiquitin, ubiquitin-
C-terminal hydroxylase, microtubule-associated protein, DJ-1, 
tau, α-synuclein, and various proteins.
9,10 α-synuclein has been 
regarded as the key pathological molecule for several reasons. 
First, genetic alterations (including point mutations and multiplica-
tions) of the α-synuclein gene cause familial PD.
11-14 Second, 
α-synuclein can take the form of a soluble oligomer, fibril, or 
sheet structure by self aggregation, depending on the microen-
vironmental conditions.
15-17 Recent studies have shown that 
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Background and PurposezzThe detection of α-synuclein in the body fluids of patients with synu-
cleinopathy has yielded promising but inconclusive results, in part because of conformational chang-
es of α-synuclein in response to environmental conditions. The aim of this study was to determine 
the feasibility of using α-synuclein as a biological marker for Parkinson’s disease (PD).
MethodszzTwenty-three drug-naïve patients with PD (age 62.4±12.7 years, mean±SD; 11 males) 
and 29 age- and sex-matched neurologic control subjects (age 60.1±16.2 years; 16 males) were re-
cruited. The levels of oligomeric and total α-synuclein in the cerebrospinal fluid (CSF) and plasma 
were measured using two simultaneous enzyme-linked immunosorbent assays.
ResultszzThe level of α-synuclein oligomer in the CSF of PD patients was significantly higher in 
PD patients than in neurological controls, but other findings (plasma α-synuclein oligomer and total 
α-synuclein in CSF and plasma) did not differ significantly between the two groups. When the con-
trol subjects were divided into a symptomatic control group (11 patients who complained of par-
kinsonian symptoms and were diagnosed with hydrocephalus and drug-induced or vascular parkin-
sonism) and a neurologic control group (10 normal subjects and 8 patients with diabetic oph-
thalmoplegia), the level of α-synuclein oligomer in the CSF was still significantly higher in PD patients 
than in both of the control subgroups.
ConclusionszzThese findings provide further evidence for a pathogenic role of the α-synuclein 
oligomer and suggest that CSF levels of α-synuclein oligomer can be a reliable marker for PD.
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the soluble oligomeric form of α-synuclein induces neuronal cell 
injury and that the Lewy body might be an end-product of the 
sequestration of this toxic molecule with other proteins, as a 
type of cell-protective mechanism.
18,19 Third, α-synuclein can be 
a seed molecule, which may explain the propagation of Lewy 
body pathology from the lower brainstem to the cortex.
20-22 Ve-
sicular secretion of α-synuclein has been found without evidence 
of neuronal injury, and adjacent glial and neuronal cells could 
uptake the secreted α-synuclein.
23-25 
The finding of an extracellular location of α-synuclein and the 
search for a reliable biological maker for PD is now drawing at-
tention to this protein. Using the enzyme-linked immunosorbent 
assay (ELISA), Lee et al.
26 found that the levels of plasma α- 
synuclein were higher in patients with PD and multiple system 
atrophy than in age-matched healthy controls. In contrast, West-
ern blot analysis revealed that the plasma levels of α-synuclein 
were lower in PD patients than in control subjects.
27 Assay of α- 
synuclein in cerebrospinal fluid (CSF) produced similar con-
flicting results to those seen in plasma; Mollenhauer et al.
28 
reported that the CSF level of α-synuclein was lower in pa-
tients with PD and dementia with Lewy bodies than in those 
with Alzheimer’s disease, while other researchers have found 
no such difference.
29 These discrepancies might reflect confor-
mational changes in α-synuclein and the presence of other cross-
reactive molecules.
A novel method for detecting oligomeric α-synuclein has yi-
elded notable results. El-Agnaf et al.
30 reported that the plas-
ma level of α-synuclein oligomer was significantly higher in 
PD patients than in age-matched controls. Their study used a 
specific double-ELISA method for α-synuclein oligomers, 
which demonstrated diagnostic specificity, sensitivity, and posi-
tive predictive values of 0.852, 0.529, and 0.818. The detection 
of oligomeric α-synuclein in brain extracts and in viable cells us-
ing various methods and the blocking of these oligomeric pro-
cesses has yielded promising results.
31-33 However, although such 
studies targeting oligomeric α-synuclein have produced signifi-
cant results, α-synuclein is known to undergo conformational 
changes according to the surrounding conditions. Factors such as 
membranes, metals, and oxygen metabolites such as dopamine 
could therefore contribute to the pathologic potential of 
α-synuclein.
18,34-36 Currently there is little known about the na-
tive structure of α-synuclein in living cells, and it is possible that 
dopaminergic treatment and other environmental exposures dur-
ing the clinical course of the disease induce conformational 
changes in this protein.
Therefore CSF and plasma levels of α-synuclein were ana-
lyzed in the present study using different ELISA methods for 
both the total and oligomeric forms of the protein in drug-na-
ïve patients with PD in order to determine the potential of α- 
synuclein as a biological marker for PD. 
Methods
Subjects
Drug-naïve patients with PD (23 patients, age 62.4±12.7 years, 
mean±SD; 11 males) were consecutively recruited for this 
study. All patients showed mild-to-moderate symptom severity 
(Hoehn and Yahr stage 1.5-3.0, median 2.5), and the diagnosis 
of the patients was confirmed according to clinical criteria dur-
ing follow-up visits for more than 6 months. Lumbar puncture 
and plasma sampling were conducted in the early morning af-
ter an overnight rest, prior to the administration of dopaminer-
gic medications. The control group consisted of 11 symptom-
atic patients (age 72.7±6.9 years; 6 males) who complained of 
slow movement and/or tremor and/or gait disturbance, and were 
diagnosed as having drug-induced parkinsonism (4 patients), 
hydrocephalus (6 patients), or vascular parkinsonism (1 patient). 
The symptomatic patients were diagnosed based on drug with-
drawal (for the patients with drug-induced parkinsonism), ra-
dioisotope cisternography, and therapeutic CSF drainage (for 
the patients with hydrocephalus). Movement specialists con-
firmed the diagnosis during the clinical follow-up visits for 
more than 6 months. An additional 18 subjects (age 52.4±15.4 
years; 10 males), comprising 8 with diabetic ophthalmoplegia 
and 10 normal adults, formed the neurologic control group. CSF 
and plasma samples from 15 patients with multiple sclerosis 
(age 41.3±9.6 years; 6 males) were also analyzed as an addi-
tional control group. CSF samples were collected in sterile poly-
propylene tubes, centrifuged for 10 minutes at 3,200 rpm, and 
stored as aliquots at -80ºC. Plasma samples were collected us-
ing plastic pipettes after being centrifuged at 3,000 rpm for 15 
minutes and were stored in aliquots at -80ºC. The local Institu-
tional Review Board approved the processes and all patients or 
family members provided signed written informed consent to 
participate. 
Materials
A mouse monoclonal antibody that recognized amino acid resi-
dues 121-125 of human α-synuclein, as well as a rabbit poly-
clonal antibody raised against the full-length α-synuclein of hu-
man origin were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Recombinant human α-synuclein was 
obtained from Calbiochem (San Diego, CA, USA). Sulfo-NHS-
LC-Biotin was purchased from Pierce (Rockford, IL, USA) and 
Bio-Spin-6 columns were obtained from Bio-Rad Laboratories 
(Hercules, CA, USA). Other chemicals including ExtrAvidin al-
kaline phosphatase and 4-hydroxyazobenzene-2-carboxylic acid/
avidin reagent were purchased from Sigma (St. Louis, MO, USA).
Preparation of aggregated α-synuclein
Recombinant human α-synuclein was solubilized with steril-Park MJ et al.
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ized phosphate-buffered saline [PBS; 137 mM phosphate buf-
fer and 150 mM NaCl (pH 7.4)] to produce a final concentra-
tion of 25 μM. An Eppendorf tube containing 25 μM α- 
synuclein solution was tightly sealed with Parafilm and incu-
bated at 37ºC for 4 days with continuous mixing (1,000 rpm). 
The resultant aggregated α-synuclein was aliquoted and stored 
at -80ºC until needed.
Preparation of the biotinylated antibody 
Sulfo-NHS-LC-Biotin was reacted with the mouse monoclonal 
antibody in PBS, at a 50-fold molar excess of biotin over anti-
bodies, for 2 hours. The mixture was desalted inn Bio-Spin-6 co-
lumns to remove any excess uncoupled biotin. The extent of bi-
otinylation per mole of antibody was determined with the 4-hy-
droxyazobenzene-2-carboxylic acid/avidin assay. The bio-
tinylated antibodies were stored at 4ºC until use.
ELISA to measure α-synuclein oligomer
An ELISA plate was coated by overnight incubation at 4ºC 
with 1 μg/mL nonbiotinylated mouse monoclonal antibodies in 
200 mM NaHCO3 (pH 9.6) containing 0.02% (w/v) sodium 
azide. The plate was then washed three times with PBS contain-
ing 0.05% Tween 20 (PBST), and blocked with PBST contain-
ing 2% bovine serum albumin for 2 hours at 37ºC. After three 
further washes with PBST, 100 μL of α-synuclein monomer, 
aggregated α-synuclein, and samples to be tested were added to 
each well. CSF and plasma samples were used without dilution. 
The plate was incubated at 37ºC for 2 hours. After washing three 
times with PBST, 100 μL of biotinylated mouse monoclonal an-
tibody diluted to 1 μg/mL in blocking buffer was added, and the 
mixture was incubated at 37ºC for 2 hours. The wells were wash-
ed three times with PBST and incubated for 1 hour at 37ºC 
with 100 μL per well of ExtrAvidin-Alkaline phosphatase di-
luted 1 : 2,000 in blocking buffer. The wells were then washed 
three times with PBST and the enzyme substrate p-nitrophenyl 
phosphate was added. The reaction was allowed to proceed for 
30 minutes at room temperature, and then the absorbance was 
read at 405 nm on a microplate ELISA reader (EL312e, Bio-Tek).
ELISA to measure total α-synuclein
The same ELISA protocol was applied to measure the total 
α-synuclein in the samples, except that a rabbit polyclonal anti-
α-synuclein antibody (1 μg/mL) and biotinylated antirabbit anti-
body were used as detecting antibodies.
Statistical analysis
Data analysis was performed with SPSS 14.0 software (SPSS, 
Chicago, IL, USA). The significance of intergroup differences 
was evaluated by one-way analyses of variance, while Student’s 
t-test was used to evaluate single comparisons. Pearson’s cor-
relation was used to evaluate the association between the lev-
els of α-synuclein and the clinical characteristics of the cohort. 
Differences were considered significant at p<0.05.
Results
Characteristics of the subjects
The control subjects were matched for age and sex with the PD 
patients. The initial CSF and plasma laboratory values did not 
differ significantly between the two groups (Table 1). When the 
control subjects were divided into symptomatic control and 
neurologic control subgroups, the only significant difference 
from the PD group was found for age in the symptomatic con-
trol group (Table 2).
Validation of ELISA methods for total 
and oligomeric form of α-synuclein
Aggregated α-synuclein was detected more sensitively by ELI-
SA for oligomeric α-synuclein than by the conventional meth-
od that detects total α-synuclein (Fig. 1). The conventional ELI-
SA method for total α-synuclein gave an optical density (OD) 
reading of 1 for monomeric α-synuclein at a concentration of 5 
μM, but the same method produced an OD reading below 0.5 
for aggregated α-synuclein at the same concentration. The OD 
using the ELISA method for oligomers was 1 for aggregated 
α-synuclein at a concentration of 10 μM, for monomeric α-synu-
clein at the same concentration it was only 0.5. These results 
show that the ELISA method for oligomeric α-synuclein is a 
sensitive one for the measurement of levels of oligomer in ag-
gregated α-synuclein. Therefore, the subsequent results are pre-
sented as the OD value, of which α-synuclein oligomer was 
measured by the oligomeric ELISA method, and total α-synuclein 
Table 1. Characteristics of the subjects
Patients (n=23) Controls (n=29) p
Age (years) 62.4±12.7 60.1±16.2 NS
Sex (male : female) 11 : 12 16 : 13 NS
CSF pH 7.45±0.37 7.33±0.33 NS
CSF cell count (n/mm3) 0.74±1.32 0.55±2.22 NS
CSF protein (mg/dL) 33.17±11.15 38.66±12.66 NS
CSF: cerebrospinal fluid, NS: not significant.α-Synuclein Oligomer in CSF of PD Patients
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was measured by the conventional ELISA method.
Total and oligomeric forms of α-synuclein 
in the CSF and plasma
The absorbance of CSF oligomeric α-synuclein was signifi-
cantly higher in patients with PD than in the control subjects 
(Table 3)(Figs. 2 and 3). However, there was no difference in 
total α-synuclein from the CSF and plasma oligomeric and total 
α- synuclein (Figs. 2 and 4). A subgroup comparison of the 
control subjects with the PD patients revealed no significant 
difference (Table 3)(Fig. 5); when the control group was subdi-
vided into symptomatic and neurologic control subgroups, the 
level of α-synuclein did not differ between the control sub-
groups. Although subjects in the symptomatic control group 
were older and those in the neurologic control group were 
younger than the patient group, the CSF α-synuclein level was 
significantly higher in the patients group than in the control 
groups. The total level of α- synuclein in the CSF and plasma 
did not differ between the patient group and the subgroups of 
control subjects. Moreover, the CSF level of α-synuclein oligo-
mer was significantly higher in patients with PD than in the 
multiple sclerosis patients.
The absorbance of neither oligomeric nor total α-synuclein 
in the sample of CSF or plasma was not correlated with any of 
the clinical parameters (i.e., age, duration of symptoms, or se-
verity of motor symptoms; data not shown). 
Discussion
α-synuclein is a classical cytoplasmic protein that exists unfold-
ed in its native form.
37 However, numerous transient structures 
can be found from monomers to oligomers and filamentous 
forms, depending on the environment.
38 Although the function-
al role of α-synuclein has not yet been established, its membrane 
binding-affinity and presynaptic location of α-synuclein indi-
cate a role in synaptic transmission.
39,40 The classical concept 
is one of a cytoplasmic location for α-synuclein, and also the pa-
thologic implications of α-synuclein have been widened with 
recent studies that have produced evidence for an extracellular 
location for α-synuclein in the body fluids of patients with PD. 
Along with the suggestion of Braak et al.,
20 pathologic studies 
have shown a Lewy body-like pathology in grafted neurons of 
autopsied brains in patients with PD after embryonic nigral cell 
transplantation, which might indicate disease propagation from 
Table 2. Comparison of α-synuclein levels (expressed as absorbance at 405 nm) between PD patient and three subgroups of control subjects
PD
patients (n=23)
Symptomatic
control (n=11)
p*
Neurologic
control (n=18)
p*
MS
patients (n=15)
p*
Age (years) 62.4±12.7 72.7±6.90 0.005 52.4±15.4 0.028 41.3±9.68 0.000 
Sex (male : female) 11 : 12 6 : 5 NS 10 : 8 NS 6 : 9 NS
Duration of symptoms 
  (years)
2.2±2.3 1.4±2.0 NS
MMSE scores 26.5±3.6 24.9±5.40 NS
CSF oligomeric
  α-synuclein
0.33±0.25 0.13±0.02 0.001 0.18±0.11 0.014  0.21±0.10 0.039
CSF total
  α-synuclein
0.14±0.02 0.13±0.02 0.655 0.13±0.03 0.273  0.14±0.02 0.984
Plasma oligomeric
  α-synuclein
0.16±0.07 0.20±0.08 0.156 0.14±0.05 0.532  0.14±0.03 0.447
Plasma total
  α-synuclein
0.16±0.03 0.14±0.02 0.369 0.15±0.02 0.514  0.16±0.03 0.642
*vs. PD patients.
PD: Parkinson’s disease, MMSE: mini mental status examination, MS: multiple sclerosis, CSF: cerebrospinal fluid, NS: not significant.
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Fig. 1. Validation of ELISA methods for 
total and oligomeric forms of α-synuclein. 
The conventional ELISA (A) and oligo-
meric methods (B) were selectively sen-
sitive to monomeric and aggregated α- 
synuclein, respectively. ELISA: enzyme-
linked immunosorbent assay.Park MJ et al.
www.thejcn.com  219
host to graft.
41,42 These findings imply the importance of extra-
cellular α-synuclein in the pathogenesis of PD, but no role for 
α-synuclein in the body fluids has been established yet.
Using different ELISA methods to detect both the total and 
oligomeric forms α-synuclein, we found that levels of the α- 
synuclein oligomer in the CSF were significantly higher in PD 
patients than in their non-PD counterparts; however, the plas-
ma levels of α-synuclein did not differ between the PD patients 
and the controls. These findings are contrary to some previous 
studies that found increased plasma and decreased CSF levels 
of α-synuclein.
26,28,43 However, those studies were based on a 
single method for detecting α-synuclein, which disregarded the 
conformational status of this protein. In addition, the study pa-
tients had been treated with dopaminergic drugs. The study 
found elevated levels of α-synuclein oligomer in the patients’ 
plasma using the oligomer-detecting method also recruited pa-
tients who had already been exposed to dopaminergic drugs.
30 
The authors of that report found elevated levels of α-synuclein 
oligomer in postmortem CSF samples of patients. As mentioned 
above, the precise native structure of α-synuclein in living cells 
remains to be determined. These conflicting results might there-
fore be attributable to the unstable structure of α-synuclein. 
Table 3. Levels of total and oligomeric forms of α-synuclein (expressed as absorbance at 405 nm) in the subjects  
Patients (n=23) Control (n=29) p
CSF oligomeric α-synuclein 0.33±0.25 0.16±0.09 0.005
CSF total α-synuclein 0.14±0.02 0.13±0.02 0.316
Plasma oligomeric α-synuclein 0.16±0.07 0.16±0.06 0.705
Plasma total α-synuclein 0.16±0.03 0.15±0.02 0.340
CSF: cerebrospinal fluid.
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Fig. 2. Levels of total and oligomeric form of α-synuclein in CSF. Solid and white bars indicate measurements using the oligomeric and con-
ventional methods, respectively. CSF: cerebrospinal fluid, PD: Pakinsonʼs disease.
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However, the design of our study employing a dual ELISA 
method for simultaneous measurement of total and oligomeric 
α-synuclein eliminated the possible confusion arising from such 
conformational changes in α-synuclein. We were also able to 
exclude the potential confounding effect of dopamine, which is 
known to be an inducer of α-synuclein oligomerization, since 
our patients had not been exposed to that drug.
44 
The meaning of elevated CSF levels of α-synuclein oligomer 
in PD patients is not easy to interpret. For example, we do not 
know whether α-synuclein oligomer levels are elevated in the 
CSF itself, or whether the oligomerization of α-synuclein is el-
evated in the milieu of the CSF. Although elevated levels of α- 
synuclein oligomer in the autopsied brain extracts of patients 
with dementia with Lewy bodies has been reported recently, 
the prevailing intracellular environment would differ from that 
of the CSF.
31 However, the finding of an intravesicular local-
ization of α-synuclein, and this being more prone to aggrega-
tion and secretion from cells by exocytosis, could provide an 
explanation for our results.
23 There is also evidence of a role of 
extracellular α-synuclein oligomer in the pathology of in vitro 
neuronal cell death, and the aggregation process appears to be 
dependent upon the concentration of α-synuclein.
25,45-47 These 
findings support the importance of elevated α-synuclein oligo-
mer in the extracellular space and in the CSF, as indicated in 
our results. In fact, it has been suggested that neuronal cells are 
subject to the worst pathologic conditions during the early stage 
of PD, prior to medication with dopaminergic agents, because 
the increased turnover of dopamine in the brain could damage 
the surrounding tissues. This condition could also contribute to 
the increase in α-synuclein in the brain, which would lead to in-
creases in CSF α-synuclein oligomer. Therefore, we suggest that 
the CSF level of α-synuclein oligomer is a useful biological mark-
er for PD, especially in the dopaminergic drug-naïve condition.
Some reports have indicated that the level of α-synuclein is 
correlated with disease duration, cognitive function, and age, 
and suggested that synaptic loss or neuronal degeneration could 
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be related to the level of α-synuclein.
29,43 We did not find any 
correlations between these clinical factors and the level of 
α-synuclein in either the plasma or the CSF. The CSF level of 
α-synuclein oligomer was significantly higher in the patients 
with PD than in both the younger control group and the pa-
tients with multiple sclerosis who already had multiple brain 
and spinal cord lesions. These findings suggest that age and le-
sions of the brain or spinal cord were not associated with the 
level of α-synuclein, although pathological differences do ex-
ist between multiple sclerosis and PD.
Our study was subject to several limitations. First, even th-
ough movement specialists diagnosed the patients with par-
kinsonian conditions of different etiologies and confirmed the 
diagnosis over a clinical follow-up period of longer than 6 
months, there is a possibility of diagnostic uncertainty. Objec-
tive diagnostic tests (e.g., dopamine-transporter imaging) and 
longer clinical observation periods of the patients groups could 
increase the reliability of any noted intergroup differences. Sec-
ond, there was a wide range of absorbance reading for the CSF 
level of α-synuclein oligomer. Nearly half of the subjects ex-
hibited an overlap, as shown in Figs. 4 and 5. Although these 
overlaps diminished with increments of age in symptomatic con-
trol subjects, more sensitive measures are needed for this to be 
considered a reliable marker. As suggested in the consensus re-
garding Alzheimer’s disease, an ideal marker should detect fun-
damental features of the disease neuropathology and should 
have a diagnostic sensitivity and specificity of over 80%. Third, 
the exact target for different ELISA methods should be ad-
dressed. Since we do not know the precise form in which α- 
synuclein exists in cells, intercellular spaces, or body fluids, tar-
get specification in the controlled condition might shed light on 
α-synuclein dynamics.
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